论文部分内容阅读
乙型肝炎病毒(HBV)感染呈世界性流行。据世界卫生组织报道全球约3.5亿人为慢性HBV感染者,我国现有慢性乙型病毒性肝炎患者2000万例[1]。慢性乙型病毒性肝炎易发展为肝硬化、肝衰竭和肝癌,其治疗主要包括抗病毒、免疫调节、抗炎和抗氧化、抗纤维化和对症治疗[2],然而只有极少数患者可以通过单纯的抗病毒治疗获得临床痊愈[3]。随着对慢性乙型病毒性肝炎免疫学发病机制的研究不断深入,发
Hepatitis B virus (HBV) infection is worldwide. According to the World Health Organization reported that about 350 million people worldwide are chronic HBV infection, China’s existing 20 million patients with chronic hepatitis B [1]. Chronic hepatitis B is susceptible to cirrhosis, liver failure and liver cancer. Its treatment includes antiviral, immunomodulatory, anti-inflammatory and anti-oxidant, antifibrotic and symptomatic treatment [2], however, only a minority of patients can pass Simple antiviral therapy clinically cured [3]. With the study of the pathogenesis of chronic hepatitis B immunology continue to develop